Blackberry 2016 Annual Report Download - page 52

Table of Contents
43
bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with
creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or
b) has, within the 10 years before this AIF, become bankrupt, made a proposal under any legislation relating to
bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with
creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the director, executive
officer or shareholder.
On November 7, 2006, as a result of the Company failing to file its second quarter financial statements for fiscal 2007 before
the statutory filing deadline of October 17, 2006, a management cease trade order (the “MCTO”) was issued by the Ontario
Securities Commission (the “OSC”) that applied to certain of the Company’s senior officers and other insiders of the Company
at that time, including Ms. Stymiest. The MCTO prohibited trading in the Company’s securities by its senior officers, directors
and certain insiders during the time that the MCTO was in effect. The MCTO was revoked on May 23, 2007 after the required
securities filings were made by the Company with the OSC.
On July 17, 2009, Luna Innovations Inc. (“Luna”) filed a voluntary petition for relief to reorganize under Chapter 11 of the
United States Bankruptcy Code , including a proposed plan of reorganization with the United States Bankruptcy Court for the
Western District of Virginia (the “Bankruptcy Court”). On January 12, 2010, the Bankruptcy Court approved the plan and Luna
emerged from bankruptcy on that date. Mr. Daniels was a member of the board of Luna from June 2007 until his resignation
on July 16, 2009.
On November 21, 2013, TranSwitch Corporation (“TranSwitch”) filed a voluntary petition for relief under Chapter 7 of the
United States Bankruptcy Code in the United States Bankruptcy Court for the District of Connecticut. Mr. Lynch was a
member of the board of directors of TranSwitch from November 2010 and the chairman of the board from July 2012, until
termination of the board on the date of the bankruptcy filing when a trustee was appointed.
On December 28, 2015, Kalobios Pharmaceuticals, Inc. (“Kalobios”) filed a voluntary petition for protection under Chapter 11
of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Dr. Smaldone Alsup
was a member of the board of directors of Kalobios from October 2013 until her resignation on November 19, 2015.
Conflicts of Interest
There is no existing or, to the Company’s knowledge, potential material conflict of interest between the Company or a
subsidiary of the Company and any director or officer of the Company or a subsidiary of the Company. See also “Interest of
Management and Others in Material Transactions” in this AIF.
AUDIT AND RISK MANAGEMENT COMMITTEE
The Audit and Risk Management Committee’s purpose is to provide assistance to the Board in fulfilling its legal and fiduciary
obligations with respect to matters involving the accounting, auditing, financial reporting, internal control, and legal
compliance and risk management functions of the Company and its subsidiaries. It is the objective of the Audit and Risk
Management Committee to maintain free and open means of communications among the Board, the independent auditors and
the financial and senior management of the Company. The full text of the Audit and Risk Management Committee’s Charter is
included as Appendix A to this AIF.
Applicable securities laws require that, subject to certain exceptions, all members of the Audit and Risk Management
Committee be “independent” under Sections 1.4 and 1.5 of National Instrument 52-110 of the Canadian Securities
Administrators - Audit Committees and the rules and regulations of NASDAQ, and “financially literate”, meaning that the
committee member has the ability to read and understand a set of financial statements that present a breadth and level of
complexity of accounting issues that are generally comparable to those issues reasonably expected to be raised by the
Company’s financial statements. Ms. Stymiest (Chair), Mr. Dattels, Dr. Smaldone Alsup and Mr. Wouters are the members of
the Audit and Risk Management Committee, and each is an independent director of the Company and financially literate, based
on his or her education and experience as described below. The Audit and Risk Management Committee has also developed, in
conjunction with the Company’s Chief Financial Officer and other accounting personnel and representatives of the Company’s
external auditors, an orientation and continuing education program that will provide the new members of the Audit and Risk
Management Committee with additional information and understanding about the accounting and financial presentation issues
underlying the Company’s financial statements.
The members of the Audit and Risk Management Committee bring significant skill and experience to their responsibilities
including professional experience in accounting, business, management and governance, and finance. The specific education
and experience of each member that is relevant to the performance of his or her responsibilities as such member of the Audit
and Risk Management Committee are set out below:
Barbara Stymiest, FCPA, FCA (Chair) – Ms. Stymiest has an HBA from the Richard Ivey School of Business, University of
Western Ontario and an FCA from the Chartered Professional Accountants of Ontario. From 2004 to 2011, Ms. Stymiest held